XWXiao Wang

Xiao Wang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Xiao Wang has a total of 32 co-authors. Here are the top co-authors by number of shared publications:

  • Amudha Ramchandran

    Natural Products Discovery Core, Life Sciences Institute, University of Michigan, Ann Arbor, MI, 48109, USA

    1 shared publication
  • Ashootosh Tripathi

    Natural Products Discovery Core, Life Sciences Institute, University of Michigan, Ann Arbor, USA

    1 shared publication
  • Bo Zhou

    College of Life Science, Northeast Forestry University, Harbin 150040, China

    1 shared publication
  • Chengwu Liu

    MOE Key Laboratory for Cellular Dynamics, Division of Life Sciences and Medicine, School of Life Sciences University of Science and Technology of China Hefei 230027 China

    1 shared publication
  • Corrie L. Sakowski

    Van Andel Research Institute, Department of Metabolism and Nutritional Programing, Grand Rapids, MI, 49503, USA

    1 shared publication
  • Darrick R. Gates

    Van Andel Research Institute, Department of Metabolism and Nutritional Programing, Grand Rapids, MI, 49503, USA

    1 shared publication

Latest Publications

  • Open Access

    Bacterial-derived cyclic lipopeptides suppress dauer arrest in C. elegans

    by Xiao Wang, Kelsie M. Nauta, Marco E. Mechan-Llontop, Darrick R. Gates, Nirmal Chaudhary, Amudha Ramchandran, Kersten K. Sykes, Corrie L. Sakowski, Vashnie H. Hartwell, Jade Tarango, et al.

    Secondary bacterial metabolites can regulate animal physiology, but the specific bacterial genes and molecules responsible for regulating, synthesizing, and transporting these molecules and the mechanisms by which they impact animal physiology often remain unclear. Here, we used Caenorhabditis elegans dauer formation as a gross morphological readout to identify bacterial mechanisms that promote development when animal TGF-β or insulin signaling is impaired. We found that the native C. elegans microbiome constituent, Pseudomonas lurida , suppresses dauer arrest and that this activity requires the two-component system, GacS/GacA, and the downstream massABC nonribosomal peptide synthetase cluster. Using sequential chromatography followed by mass spectrometry and NMR, we identified Massetolide F, a bacterial cyclic lipopeptide biosurfactant, as a massABC -dependent product. In addition, we found that purified Massetolide F was sufficient to restore dauer suppression to P. lurida ΔmassBC . We also found that surfactin C, a cyclic lipopeptide from B. subtilis , similarly suppressed dauer formation whereas the cyclic lipopeptide antibiotic daptomycin did not, indicating that dauer suppression is shared by a subset of cyclic lipopeptides rather than being a general property of the class. Lastly, we found that massABC -dependent Massetolide F production induces the expression of the acid sphingomyelinase asm-3 in C. elegans, that asm-3 is required for Massetolide F induced dauer suppression, and that loss of Massetolide F production also leads to reduced bacterial clearance in host animals. Together, these findings identify Massetolide F as a microbiome-derived molecule that promotes animal development and reveal an unexpected function for bacterial biosurfactants in regulating animal physiology.


  • Open Access

    Deciphering the effects of PYCR1 on cell function and its associated mechanism in hepatocellular carcinoma

    by Yanzhen Xu, Wenpu Zuo, Xiao Wang, Qinle Zhang, Xiang Gan, Ning Tan, Wenxian Jia, Jiayi Liu, Zhouquan Li, Bo Zhou, et al.

    Overexpression of pyrroline-5-carboxylate reductase 1 (PYCR1) has been associated with the development of certain cancers; however, no studies have specifically examined the role of PYCR1 in hepatocellular carcinoma (HCC). Based on The Cancer Genome Atlas expression array and meta-analysis conducted using the Gene Expression Omnibus database, we determined that PYCR1 was upregulated in HCC compared to adjacent nontumor tissues (P < 0.05). These data were verified using quantitative real-time polymerase chain reaction, western blotting, and immunohistochemistry analysis. Additionally, patients with low PYCR1 expression showed a higher overall survival rate than patients with high PYCR1 expression. Furthermore, PYCR1 overexpression was associated with the female sex, higher levels of alpha-fetoprotein, advanced clinical stages (III and IV), and a younger age (< 45 years old). Silencing of PYCR1 inhibited cell proliferation, invasive migration, epithelial-mesenchymal transition, and metastatic properties in HCC in vitro and in vivo. Using RNA sequencing and bioinformatics tools for data-dependent network analysis, we found binary relationships among PYCR1 and its interacting proteins in defined pathway modules. These findings indicated that PYCR1 played a multifunctional role in coordinating a variety of biological pathways involved in cell communication, cell proliferation and growth, cell migration, a mitogen-activated protein kinase cascade, ion binding, etc. The structural characteristics of key pathway components and PYCR1-interacting proteins were evaluated by molecular docking, and hotspot analysis showed that better affinities between PYCR1 and its interacting molecules were associated with the presence of arginine in the binding site. Finally, a candidate regulatory microRNA, miR-2355-5p, for PYCR1 mRNA was discovered in HCC. Overall, our study suggests that PYCR1 plays a vital role in HCC pathogenesis and may potentially serve as a molecular target for HCC treatment.


  • Open Access

    Knockdown of DDX46 Inhibits the Invasion and Tumorigenesis in Osteosarcoma Cells

    by Feng Jiang, Dengfeng Zhang, Guojun Li, Xiao Wang

    DDX46, a member of the DEAD-box (DDX) helicase family, is involved in the development of several tumors. However, the exact role of DDX46 in osteosarcoma and the underlying mechanisms in tumorigenesis remain poorly understood. Thus, in the present study, we explored the role of DDX46 in osteosarcoma and the underlying mechanisms. Our results demonstrated that the expression levels of DDX46 in both mRNA and protein were greatly elevated in human osteosarcoma tissues and cell lines. Knockdown of DDX46 obviously inhibited osteosarcoma cell proliferation and tumor growth in vivo. In addition, knockdown of DDX46 also significantly suppressed migration and invasion in osteosarcoma cells. Furthermore, knockdown of DDX46 substantially downregulated the phosphorylation levels of PI3K and Akt in SaOS2 cells. In summary, the present results have revealed that DDX46 plays an important role in osteosarcoma growth and metastasis. Knockdown of DDX46 inhibited osteosarcoma cell proliferation, migration, and invasion in vitro and tumor growth in vivo. Therefore, DDX46 may be a potential therapeutic target for the treatment of osteosarcoma.